Measurement of Biochemical Markers of Bone Resorption

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 541-563

  Kraenzlin, Marius E ^a   Seibel, Markus J ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 52349116850     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50034-0     Document Type: Chapter

References (214)

1. Prockop D.J., Kivirikko K.I. Heritable diseases of collagen. N. Engl. J. Med. 1984, 311:376-386.
2. Smith R. Collagen and disorders of bone. Clin. Sci. 1980, 59:215-221.
3. Woessner J.F. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch. Biochem. Biophys. 1961, 93:440-447.
4. Kivirikko K.I., Laitinen O., Prockop D.J. Modifications of a specific assay for hydroxyproline in urine. Analyt. Biochem. 1967, 19:249-255.
5. Podenphant J., Larsen N.E., Christiansen C. An easy and reliable method for determination of urinary hydroxyproline. Clinica. Chimica. Acta. 1984, 142:145-148.
6. Sela B.A., Doolman R. Refinement of a specific assay for hydroxyproline in urine. Clin. Chem. Acta. 1991, 203:91-94.
7. Hodgkinson A., Thompson T. Measurement of the fasting urinary hydroxyproline: creatinine ratio in normal adults and its variation with age and sex. J. Clin. Pathol. 1982, 35:807-811.
8. Mautalen C.A. Circadian rhythm of urinary total and free hydroxyproline excretion and its relation to creatinine excretion. Cli. Experimental. 1970, 75:11-18.
9. Scalella P. Interference by iodinated contrast media in total urinary hydroxyproline measurement. Lancet 1982, 1(8277):907.
10. Reed P., Holbrock I.B., Gardner M.L.G., McMurray J.R. Simple, optimized liquid-chromatographic method for measuring total hydroxyproline in urine evaluated. Clin. Chem. 1991, 37:285-290.
11. Casari E., Ferrero C.A., Grazioli V., Murone M. Performance of a modified HPLC method to determine total hydroxyprolinuria in 2-h urine samples. Clin. Chem. 1992, 38:2337-2338.
12. Dawson C.D., Jewett S., Driskoll W.J. Liquid-chormatographic determination of total hydroxyproline in urine. Clin. Chem. 1988, 34:1572-1574.
13. Cunningham L.W., Ford J.D., Segrest J.P. The isolation of identical hydroxylysyl glycosides from hydrolysates of soluble collagen and from human urine. J. Biol. Chem. 1967, 242:2570-2571.
14. Krane S.M., Kantrowitz F.G., Byrns M., Pinnell S.R., Singer F.R. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. J. Clin. Invest. 1977, 39:819-827.
15. Askenasi R. Urinary excretion of free hydroxylysine, peptide-bound hydroxylysine and hydroxylysyl glycosides in physiological conditions. Clin. Chim. Acta. 1975, 59:87-92.
16. Segrest J.P., Cunningham L.W. Variations in human urinary O-hydroxylysyl glycoside levels and their relationship to collagen metabolism. J. Clin. Invest. 1970, 49:1497-1509.
17. Krane S.M., Kantrowittz F.G., Byrne M., Pinnell S.R., Singer F.R. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. J. Clin. Invest. 1977, 59:819-827.
18. Moro L., Modricky C., Stagni N., Vittur F., Bernard B. High-performance liquid chromatographic analysis of urinary hydroxylysyl glycosides as indicator of collagen turnover. Analyst 1984, 109:1621-1622.
19. Moro L., Battista C., Modricky C., Rovis L., de Bernard B. High-performance liquid chromatographic preparation of galactosyl-hydroylysine, a specific bone collagen marker. J. Chromat. 1989, 490:285-292.
20. Moro L., Modricky C., Rovis L., de Bernard B. Determination of galactosyl hydroxylysine in urine as a means for the identification of osteoporotic women. Bone Min. 1988, 3:271-276.
21. Moro L., Gazzarrini C., Modricky C., Rovis L., de Bernard B., Galligioni E., Crivellari D., Morassut S., Monfardini S. High predictivity of galactosyl-hydroxylysine in urine as an indicator of bone metastases from breast cancer. Clin. Chem. 1990, 36:772-774.
22. Leigh S.D., Ju H.S., Lundgard R., Daniloff G.Y., Liu V. Development of an immunoassay for urinary galactosylhydroxylysine. J. Immunol. Methods 1998, 220:169-178.
23. Blumsohn A., Hannon R.A., Eastell R. Biochemical assessment of skeletal activity. Phys. Med. and Rehab. Clin. North Am. 1995, 6:483-505.
24. al-Dehaimi A.W., Blumsohn A., Eastell R. Serum galactosyl hydroxylysine as a biochemical marker of bone resorption. Clin. Chem. 1999, 45:676-681.
25. Bettica P., Moro L., Robins S.P., Taylor A.K., Talbot J., Singer F.R., Baylink D.J. Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared. Clin. Chem. 1992, 38:2313-2318.
26. Moro L., Mucelli R.S., Gazzarrini C., Modricky C., Marotti F., de Bernard B. Urinary beta-1-galactosyl-O-hydroxylysine (GH) as a marker of collagen turnover of bone. Calc. Tiss. Int. 1998, 42:87-90.
27. Robins S.P. Cross-linking of collagen. Isolation, structural characterization and glycosylation of pyridinoline. J. Biochem. 1983, 215:167-173.
28. Eyre D.R., Paz M.A., Gallop P.M. Cross-linking in collagen and elastin. Ann. Rev. Biochem. 1984, 53:717-748.
29. Delmas P.D., Gineyts E., Betholin A., Garnero P., Marchand F. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J. Bone Min. Metab. 1993, 8:643-648.
30. Colwell A., Russell R.G.G., Estell R. Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Europ. J. Clin. Invest. 1993, 23:341-349.
31. McLaren A.M., Isdale A.H., Whitings P.H., Bird H.A., Robins S.P. Physiological variations in the urinary excretion of pyridinium crosslinks of collagen. Br. J. Rheumatol. 1993, 32:307-312.
32. Colwell A., Eastell R. The renal clearance of free and conjugated pyridinum cross-links of collagen. J. Bone Miner. Res. 1996, 11:1976-1980.
33. Huber F., Traber L., Roth H.J., Heckel V., Schmidt-gayk H. Markers of bone resorption-measurement in serum, plasma or urine?. Clin. Lab. 2003, 49:203-207.
34. Black D., Duncan A., Robins S.P. Quantitative analysis of the pyrdinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal. Biochem. 1988, 169:197-203.
35. Uebelhart D., Gineyts E., Chapuy M.-C., Delmas P.D. Urinary excretion of pyridinium crosslinks: A new marker of bone resorption in metabolic bone disease. Bone Mineral 1990, 8:87-96.
36. Pratt D.A., Daniloff Y.N., Duncan A., Robins S.P. Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Anal. Biochem. 1992, 207:168-175.
37. Robins S.P., Stead D.A., Duncan A. Precautions in usings internal standard to measure pyridinoline and deoxypyrinoline in urine. Clin. Chem. 1994, 40:2322-2323.
38. Bank R.A., Beekman B., Verzijl N., de Roos J.A., Sakkee A.N., TeKoppele J.M. Sensitive fluorimetric quantitation of pyridinium and pentosidine crosslinks in biological samples in a single high-performance liquid chromatographic run. J. Chromatogr. B. Biomed. Sci. Appl. 1997, 703:37-44.
39. Vesper H.W., Audain C., Woolfitt A., Ospina M., Barr J., Robins S.P., Myers G.L. High-performance liquid chromatography method to analyze free and total urinary pyridinoline and deoxypyridinoline. Analyt. Biochem. 2003, 318:204-211.
40. Calabresi E., Lasagni L., Franceschelli F., Bartolini L., Serio M., Brandi M.L. Use of an internal standard to measure pyridinoline and deoxypyridinoline in urine. Clin. Chem. 1994, 40:336-337.
41. Jensen J.B., Kollerup G., Sorensen A., Sorensen O.H. Intraindividual variability of bone markers in the urine. Scand. J. Clin. Lab. Invest. 1997, 57:29-34.
42. Vesper H.W., Smith S.J., Audain C., Myers G.L. Comparison study of urinary pyridinoline and deoxypyridinoline. Clin. Chem. 2001, 47:2029-2031. (GENERIC) Ref Type: Generic.
43. Robins S.P., Duncan A., Wilson N., Evans B.J. Standarization of pyridinium crosslinks, pyridinoline and deoxypyridinoline, for use as biochemical markers of collagen degradation. Clin. Chem. 1996, 42:1621-1626.
44. Waelchli R., Beerli C., Meigel H., Revesz L. First total synthesis of the bone resorption markers deoxypyridinoline and hydroxypyridinoline. Chem. Lett. 1997, 7:2831-2836.
45. Allevi P., Longo A., Anastasia M. Total synthesis of deoxypyridinoline, a biochemical marker of collagen turnover. Chem. Commun. 1999, 32:559-560.
46. Seibel M.J., Duncan A., Robins S.P. Urinary hydroxypyridinium crosslinks provide indices of cartilage and bone involvement in arthritic disease. J. Rheumatol. 1989, 16:964-970.
47. Seibel M.j., Baylink D.J., Farley J.R., Epstein S., Yamauchi M., Eastell R., Pols H.A., Raisz L.G., Gundberg C.M. Basic science and clinical utility of biochemical markers of bone turnover-a Congress report. Exp. Clin. Endocrinol. Diabetes. 1997, 105:125-133.
48. Peel N.F.A., al-Dehaimi A.W., Colwell A., Russel R.G.G., Eastell R. Sulfasalazine may interfere with HPLC assay of urinary pyridinium crosslinks. Clin. Chem. 1994, 40:167-168.
49. Seyedin S.M., Kung V.T., Daniloff Y.N., Hesley R.P., Gomez B., Nielsen L.A., Rosen H.N., Zuk R.F. Immunoassay for urinary pyridinoline: The new marker of bone resorption. J. Bone Miner. Res. 1993, 8:635-641.
50. Gomez B., Ardakani S., Evans B.J., Merrel L.D., Jenkins D.K., Kung V.T. Monoclonal antibody assay for free urinary pyridinium cross-links. Clin. Chem. 1996, 42:1168-1175.
51. Robins S.P., Woitge H., Hesley R., Ju J., Seyedin S., Seibel M.J. Direct enzyme-linked immunoassay for urinary deoxypyridiniloine as a specific marker for measuring bone resorption. J. Bone Miner. Res. 1994, 9:1643-1649.
52. Seibel M.J., Woitge H., Auler B., Kissling C., Ziegler R. Urinary free deoxypyridinoline: comparison of a new automated chemiluminescence immunoassay with HPLC and ELISA techniques. Clin. Lab. 1998, 44:129-135.
53. Rosano T.G., Peaston R.T., Bone H.G., Woitge H.W., Francis R.M., Seibel M. Urinary free deoxypyridioline by chemiluminescence immunoassay: analytical and clinical evaluation. Clin. Chem. 1998, 44:2126-2132.
54. Sarno M., Powell H., Tjersland G., Schoendorfer D., Harris H., Adams K., Ogata P., Warnick G.R. A collection method and high-sensitivity enzyme immunoassay for sweat pyridinoline and deoxypyridinoline cross-links. Clin. Chem. 1999, 45:1501-1509.
55. Sarno M., Sarno L., Baylink D., Drinkwater B., Farley S., Kleerekoper M., Lang R., Lappe J., Licata A., McClung M., Miller P., Nattrass S., Recker R., Schwartz E.N., Tucci J.R., Wolf S., Powell H., Tjersland G., Warnick G.R. Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease. Clin. Chem. Lab. Med. 2001, 39:223-228.
56. Kamel S., Brazier J., Neri V., Picard C., Samson L., Desmet G., Sebert J.L. Multiple molecular form of pyridinoline crosslinks excreted in human urine evaluated by chromatographic and immunoassay methods. J. Bone Miner. Res. 1995, 10:1385-1392.
57. Seibel M.J. Clinical use of pyridinium crosslinks. Calcium Regulating Hormones and Markers of bone Metabolism: Measurement and Interpretation 1997, 157-169. Clin. Lab. Publications, Heidelberg, Germany. H. Schmidt-gayk (Ed.).
58. Garnero P., Shih W.J., Gineyts E., Karpf D.B., Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 1994, 79:1693-1700.
59. Randall A.G., Kent G.N., Garcia-Webb P., Bhagat C.I., Pearce D.J., Gutteridge D.H., Prince R.L., Stewart G., Stuckey B., Will R.K., Retallack R.W., Price R.I., Ward L. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of different forms of pyridinoline cross-links. J. Bone Miner. Res. 1996, 11:1176-1184.
60. Blumsohn A., Naylor K.E., Assiri A.M., Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin. Chem. 1995, 41:1592-1598.
61. Knott L., Bailey A.J. Collagen cross-links in mineralizing tissues: a review of their chemistry, function and clinical relevance. Bone 1998, 22:181-187.
62. Hanson D., Eyre D.R. Molecular site specificity of pyridinoline and pyrrole crosslinks in type I collagen of human bone. J. Biol. Chem. 1996, 247:26508-26516.
63. Knott L., Tarlton J.F., Bailey A.J. Chemistry of collagen cross-linking: Biochemical changes in collagen during the partial mineralization of turkey leg tendon. Biochem. J. 1997, 322:535-542.
64. Kuypers R., Tyler M., Kurth L.B., Jenkins I.D., Horgan D.J. Identification of the loci of the collagen-associated Ehrlich chromagen in type I collagen confirms its role as a trivalent crosslink. Biochem. J. 1992, 283:129-136.
65. Fledelius C., Johnsen A.H., Cloos P.C., Bonde M., Qvist P. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J. Biol. Chem. 1997, 272:9755-9763.
66. Garnero P., Fledelius C., Gineyts E., Serre C.M., Vignot E., Delmas P.D. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone. J. Bone Miner. Res. 1997, 12:1407-1415.
67. Cloos P.A., Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem. J. 2000, 345(Pt 3):473-480.
68. Cloos P.A., Christgau S. Non-enzymatic covalent modifications of proteins: mechanisms, physiological consequences and clinical applications. Matrix Biol. 2002, 21:39-52.
69. Cloos P.A.C., Fledelius C., Christgau S., Engsig M., Delmas P., Body J.J., Garnero P. Investigation of bone disease unsing isomerized and racemized fragments of type I collagen. Calcified Tissue Int. 2003, 72:8-17.
70. Garnero P., Gineyts E., Schaffer A.V., Seaman J., Delmas P.D. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum. 1998, 41:354-360.
71. Reginster J.-Y., Henrotin Y., Christiansen C., Gamwell-Henriksen E., Bruyere O., Collette J., Christgau S. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type 1. Calcif. Tissue Int. 2001, 69:130-137.
72. Garnero P., Cloos P., Sornay-Rendu E., Qvist P., Delmas P.D. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J. Bone Miner. Res. 2002, 17:826-833.
73. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin. Chem. 1993, 39:635-640.
74. Garnero P., Ferreras M., Karsdal M.A., Nicamhlaoibh R., Risteli J., Borel O., Qvist P., Delmas P.D., Foged N.T., Delaisse J.M. The type 1 collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J. Bone Miner. Res. 2003, 18:859-867.
75. Hassager C., Risteli J., Risteli L., Jensen S.B., Christiansen C. The diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J. Bone Miner. Res. 1992, 7:1307-1311.
76. Eriksen E.F., Charles P., Melsen F., Mosekilde L., Risteli L., Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry. J. Bone Miner. Res. 1993, 8:127-132.
77. Okabe R., Inaba M., Nakatsuka K., Miki T., Naka H., Moriguchi A., Nishizawa Y. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type 1 collagen and urinary deoxypyridinoline. J. Bone Miner. Metab. 2004, 22:127-131.
78. Yasumizu T., Fukada Y., Hoshi K. Changes in serum levels of type 1 collagen-related proteins after surgically induced menopause and correlations with bone loss in the lumbar spine. Endocr. J. 1999, 46:337-343.
79. Meier C., Nguyen T.V., Center J.R., Seibel M.J., Eisman J.A. Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J. Bone Miner. Res. 2005, 20:579-587.
80. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Immunoassay for quantifying type 1 collagen degradation products in urine evaluated. Clin. Chem. 1994, 40:2022-2025.
81. Fledelius C., Kolding I., Bonde M., Cloos P., Christgau S. Specificity of the Crosslaps ELISA and the MabA7 ELISA. Osteoporosis Int. 1996, 6(Suppl. 1): PMO440.
82. Hanson D.A., Weis M.A., Bollen A.M., Maslan S.L., Singer F.R., Eyre D.R. A specific immunoassay for monitoring human bone resorption: quantitation of type 1 collagen cross-linked N-telopeptides in urine. J. Bone Miner. Res. 1992, 7:1251-1258.
83. Garnero P., Gineyts E., Arbault P., Christiansen C., Delmas P.D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound cross-links excretion. J. Bone Miner. Res. 1995, 10:641-649.
84. Ju H.-S.J., Leung S., Brown B., Stringer M.A., Leigh S., Scherrer C., Shepard K., Jenkins D., Knudsen J., Cannon R. Comparison of analytical performance and biological variability of three bone resorption assays. Clin. Chem. 1997, 43:1570-1576.
85. Bonde M., Fledelius C., Qvist P., Christiansen C. Coated tube radioimmunoassay for c-telopeptides of type 1 collagen to assess bone resorption. Clin. Chem. 1996, 42:1639-1644.
86. Cloos P.A., Lyubimova N., Solberg H., Qvist P., Christiansen C., Byrjalsen I., Christgau S. An immunoassay for measuring fragments of newly synthesized collagen type 1 produced during metastatic invasion of bone. Clin. Lab. 2004, 50:279-289.
87. Bonde M., Garnero P., Fledelius C., Qvist P., Delmas P.D., Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the c-telopeptide of type 1 collagen. J. Bone Miner. Res. 1997, 12:1028-1034.
88. Rosenquist C., Fledelius C., Christgau S., Pedersen B.J., Bonde M., Qvist P., Christiansen C. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin. Chem. 1998, 44:2281-2289.
89. Gamero P., Borel O., Delmas P. Evaluation of a fully automated serum assay for c-terminal cross-linking teleopeptide of type I collagen in osteoporosis. Clin. Chem. 2001, 47:694-702.
90. Schmidt-gayk H., Spanuth E., Kotting J., Bartl R., Felsenberg D., Pfeilschifter J., Raue F., Roth H.J. Performance evaluation of automated assays for beta-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin. Chem. Lab. Med. 2004, 42:90-95.
91. Srivastava A.K., MacFarlane G., Srivastava V.P., Mohan S., Baylink D.J. A new monoclonal antibody ELISA for detection and characterization of C-telopeptide fragments of type 1 collagen in urine. Calcif. Tissue Int. 2001, 69:327-336.
92. Eyre D.R. The specificity of collagen crosslinks as markers of bone and connective tissue degradation. Acta. Orthop. Scand. 1995, 66:166-170.
93. Apone S., Fevold K., Lee M., Eyre D.R. A rapid method for quantifying osteoclast activity in vitro. J. Bone Miner. Res. 1998, 9:S178. (abstract).
94. Robins S.P. Collagen cross-links in metabolic bone disease. Acta. Orthop. Scand. 1995, 66.
95. Gertz B.J., Hanson D.A., Quan H., Harris S.T., Genant H.K., Chesnut CH.H., Eyre D.R. Monitoring bone resorption in early postmenopausal women by an immunoassay for crosslinked collagen peptides in urine. J. Bone Min. Res. 1994, 9:135-142.
96. Clemens J.D., Herrick M.V., Singer F.R., Eyre D.R. Evidence that serum NTx (collagen-type 1 N-telopeptides) can act as an immunochemical marker of bone resorption. Clin. Chem. 1997, 43:2058-2063.
97. Bekker P.J., Holloway D.L., Rasmussen A.S., Murphy R., Martin S.W., Leese P.T., Holmes G.B., Dunstan C.R., DePaoli A.M. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmen opausal women. J. Bone Miner. Res. 2004, 19:1059-1066.
98. Ali S.M., Demers L.M., Leitzel K., Harvey H.A., Clemens D., Mallinak N., Engle L., Chinchilli V., Costa L., Brady C., Seaman J., Lipton A. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann. Oncol. 2004, 15:455-459.
99. Guillemant J.A., Accarie C.M., de la Gueronniere V., Guillemant S.E. Different acute responses of serum type 1 collagen telopeptides, CTX, NTX and ICTP, after repeated ingestion of calcium. Clin. Chim. Acta. 2003, 337:35-41.
100. Scariano J.K., Garry P.J., Montoya G.D., Duran-Valdez E., Baumgartner R.N. Diagnostic efficacy of serum cross-linked N-telopeptide (NTx) and aminoterminal procollagen extension propeptide (PINP) measurements for identifying elderly women with decreased bone mineral density. Scand. J. Clin. Lab. Invest. 2002, 62:237-243.
101. Greenspan S.L., Rosen H.N., Parker R.A. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J. Clin. Endocrinol. Metab. 2000, 85:3537-3540.
102. Fall P.M., Kennedy D., Smith J.A., Seibel M.J., Raisz L.G. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men. Osteoporos Int. 2000, 11:481-485.
103. Chandani A.K., Scariano J.K., Glew R.H., Clemens J.D., Garry P.J., Baumgartner R.N. Bone mineral density and serum levels of aminoterminal propeptides and cross-linked n-telopeptides of type 1 collagen in elderly men. Bone 2000, 26:513-518.
104. Eastell R., Mallinak N., Weiss S., Ettinger M., Pettinger M., Cain D., Flessland K., Chesnutt C. Biological variability of serum and urinary N-telopeptides of type 1 collagen in postmenopausal women. J. Bone Miner. Res. 2000, 15:594-598.
105. Scariano J.K., Glew R.H., Bou-Sherhal C.E., Clemens J.D., Garry P.J., Baumgartner R.N. Serum levels of crosslinked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone 1998, 23:471-477.
106. Scariano J.K., Vanderjagt D.J., Thacher T., Isichei C.O., Hollis B.W., Glew R.H. Calcium supplements increase the serum levels of crosslinked N-telopeptides of bone collagen and parathyroid hormone in rachitic Nigerian children. Clin. Biochem. 1998, 31:421-427.
107. Gertz B.J., Clemens J.D., Holland S.D., Yuan W., Greenspan S. Application of a new serum assay for type 1 collagen crosslinked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif. Tissue Int. 1998, 63:102-106.
108. Hannon R.A., Boreham J.V., Porter J.A., Karnik K., Eagleton A.C., Eastell R., Blumsohn A. Technical and clinical evaluation of a point of care device for measurement of N-telopeptide fragment of type I collagen in urine. J. Bone Miner. Res. 2004, 19(Suppl. 1):SU147.
109. Garnero P., Delmas P.D. An immunoassay for type I collagen alpha1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis. Bone 2003, 32:20-26.
110. Gerrits M.I., Thijssen J.H., van Rijn H. Determination of pyridinoline and deoxypyridinoline in urine, with special attention to retaining their stability. Clin. Chem. 1995, 41:571-574.
111. Beardsworth L.J., Eyre D.R., Dickson I.R. Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J. Bone Min. Res. 1990, 5:671-676.
112. Seibel M.J., Gartenberg F., Silverberg S.J., Ratcliffe A., Robins S.P., Bilezikian J.P. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1992, 74:481-486.
113. Colwell A., Hamer A., Blumsohn A., Eastell R. To determine the effects of ultraviolet light, natural light and ionizing radiation on pyridinium cross-links in bone and urine using highperformance liquid chromatography. Europ. J. Clin. Invest. 1996, 26:1107-1114.
114. Walne A.J., James I.T., Perret D. The stability of pyridinium crosslinks in urine and serum. Clin. Chem. Acta. 1995, 240:95-97.
115. Blumsohn A., Colwell A., Naylor K.E., Eastell R. Effect of light and gamma-irradiation on pyridinolines and telopeptides of type 1 collagen in urine. Clin. Chem. 1995, 41:1195-1197.
116. Eastell R., Calvo M.S., Burritt M.F., Offord K.P., Russell R.G.G., Riggs B.L. Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type 1 osteoporosis. J. Clin. Endocrinol. Metab. 1992, 74:487-494.
117. Schlemmer A., Hassager C., Jensen S.B., Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J. Clin. Endocrinol. Metab. 1992, 74:476-480.
118. Pagani F., Panteghini M. Diurnal rhythm in urinary excretion of pyridinium crosslinks. Clin. Chem. 1994, 40:952-953.
119. Schlemmer A., Hassager C., Pedersen B., Christiansen C. Posture, age, menopause, and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium crosslinks. J. Bone Miner. Res. 1994, 9:1883-1888.
120. Bollen A.M., Martin M.D., Leroux B.G., Eyre D.R. Circadian variation in urinary excretion on bone collagen cross-links. J. Bone Miner. Res. 1995, 10:1885-1890.
121. Eastell R., Simmons P.S., Assiri A.M., Burritt M.F., Russel R.G.G., Riggs B.L. Nyctohemeral changes in bone turnover assessed by serum bone gla-protein concentration and urinary deoxypyridinoline excretion: effect of growth and aging. Clin. Sci. 1992, 83:375-382.
122. Schmeller N.T., Bauer H.W. Circadian variation of different fractions of serum acid phosphatase. Prostate 1983, 4:391-395.
123. Li Y., Lang M., Kissling C., Woitge H.W., Farahmand I., Oberwittler H., Karmatschek M., Armbuster F.P., Ziegler R., Seibel M.J. Biological variability in serum immunoreactive bone sialoprotein. Clin. Lab. 1998, 44:553-555.
124. Qvist P., Christgau S., Pedersen B.J., Schlemmer A., Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002, 31:57-61.
125. Hannon R., Clowes J., Eagleton A.C., Al Hadari A., Eastell R., Blumsohn A. Clinical performance of immunoreactive tartrate resistent acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004, 34:187-194.
126. Wichers M., Schmidt E., Bidlingmaier M., Klingmüller D. Diurnal rhythm of CrossLaps in human serum. Clin. Chem. 1999, 45:1858-1860.
127. Caillot-Augusseau A., Vico L., Heer M., Voroviev D., Souberbielle J.C., Zitterman A., Alexandre C., Lafage-Proust M.H. Space flight is associated with rapid decreases of undercarboxylated osteocalcin and increases of markers of bone resorption without changes in their circadian variation: observations in two cosmonauts. Clin. Chem. 2000, 46:1136-1143.
128. Bjarnason N.H., Henriksen E.E., Alexandersen P., Christgau S., Henriksen D.B., Christiansen C. Mechanism of circadian variation in bone resorption. Bone 2002, 30:307-313.
129. Nielsen H.K., Brixen K., Mosekilde L. Diurnal rhythm and 24-hour integrated concentrations of serum osteocalcin in normals: Influence of age, sex, season, and smoking habits. Calcif. Tissue Int. 1990, 47:284-290.
130. Christgau S. Circadian variation in serum CrossLaps concentration is reduced in fasting individuals. Clin. Chem. 2000, 46:431.
131. Markowitz M.E., Arnaud S., Rosen J.F., Thorpy M., Laximinarayan S. Temporal interrelation ships between the circadian rhythms of serum parathyroid hormone and calcium concentrations. J. Clin. Endocrinol. Metab. 1988, 67:1068-1073.
132. Calvo M.S., Eastell R., Offord K.P., Bergstralh E.J., Burritt M.F. Carcadian variation in ionized calcium and intact parathyroid hormone: Evidence for sex differences in calcium homeostasis. J. Clin. Endocrinol. Metab. 1991, 72:69-76.
133. Nielsen H.K., Laurberg P., Brixen K., Mosekilde L. Relations between diumal variations in serum osteocalcin, cortisol, parathyroid hormone, and ionized calcium in normal individuals. Acta. Endocrinol. (Copenh) 1991, 124:391-398.
134. Ebeling P.R., Butler P.C., Eastell R., Rizza R.A., Riggs B.L. The nocturnal increase in growth hormone is not the cause of the nocturnal increase in serum osteocalcin. J. Clin. Endocrinol. Metab. 1991, 73:368-372.
135. Henriksen D.B., Alexandersen P., Bjarnason N.H., Vilsboll T., Hartmann B., Henriksen E.E., Byrjalsen I., Krarup T., Holst J.J., Christiansen C. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J. Bone Miner. Res. 2003, 18:2180-2189.
136. Henriksen D.B., Alexandersen P., Byrjalsen I., Hartmann B., Bone H.G., Christiansen C., Holst J.J. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 2004, 34:140-147.
137. Heymsfield S.B., Artega C., McManus B.S., Smith J., Moffitt S. Measurements of muscle mass in humans: validity of the 24 hour urinary creatinine method. Am. J. Clin. Nutr. 1983, 37:478-494.
138. Popp-Snijders C., Lips P., Netelenbos J.C. Intraindividual variation in bone resorption markers in urine. Ann. Clin. Biochem. 1996, 33:347-348.
139. Blumsohn A., Hannon R.A., al-Dehaimi A.W., Eastell R. Short-term intraindividual variability of markers of bone turnover in healthy adults. J. Bone Miner. Res. 1994, 9(Suppl. 1):S153.
140. Panteghini M., Pagani F. Biological variation in bone-derived biochemical markers in serum. Scand. J. Clin. Lab. Invest. 1995, 55:609-616.
141. Garnero P., Mulleman D., Munoz F., Sornay-Rendu E., Delnas P.D. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J. Bone Miner. Res. 2003, 18:1789-1794.
142. Christgau S., Bitsch-Jensen O., Bjarnason N., Henriksen E.G., Qvist P., Alexandersen P., Henriksen D.B. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000, 26:505-511.
143. Robins S.P. Collagen markers in urine in human arthritis. Methods in Cartilage Research 1990, 349-352. Academic Press, London. A. Maroudas (Ed.).
144. Fisher L.W., McBride O.W., Termine J.D., Young M.F. Human bone sialoprotein: deduced protein sequence and chromosomal localization. J. Biol. Chem. 1990, 265:2347-2351.
145. Oldberg A., Franzen A., Heinegard D. Isolation and characterization of two sialoproteins present only in bone. Biochem. J. 1985, 232:715-724.
146. Chen J., Shapiro H.S., Wrana J.L. Localization of bone sialoprotein (BSP) expression to sites of mineral tissue formation in fetal rat tissue by in-situ hybridization. Matrix 1991, 11:133-143.
147. Shapiro H.S., Chen J., Wrana J.L., Zhang Q., Blum M., Sodek J. Characterization of porcine bone sialoprotein: primary structure and cellular expression. Matrix 1993, 13:431-440.
148. Fujisawa R., Butler W.T., Brunn J.C., Zhou H.Y., Kuboki Y. Differences in composition of cell-attachment sialoproteins between dentin and bone. J. Dent. Res. 1993, 72:1222-1226.
149. Ross F.P., Chappel J., Alvarez J.I., Sander D., Butler W.T., Farach-Carson M.C., Mintz K.A., Robey P.G., Teitelbaum S.L., Cheresh D.A. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J. Biol. Chem. 1993, 268:9901-9907.
150. Fujisawa R., Nodasaka Y., Kuboki Y. Further characterization of interaction between bone sialoprotein (BSP) and collagen. Calcif. Tissue Int. 1995, 56:140-144.
151. Hunter G.K., Kyle C.L., Goldberg H.A. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem. J. 1994, 300:723-728.
152. Young M.F., Kerr J.M., Ibaraki K., Heegaard A.M., Robey P.G. Structure, expression, and regulation of the major noncollagenous matrix proteins of bone. Clin. Orthop. 1992, 281:275-294.
153. Chenu C., Delmas P.D. Platelets contrubute to circulating levels of bone sialoprotein in human. J. Bone Miner. Res. 1992, 7:47-54.
154. Zhang J.H., Tang J., Wang J., Ma W., Zheng W., Yoneda T., Chen J. Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int. J. Oncol. 2003, 23:1043-1048.
155. Sharp J.A., Waltham M., Williams E.D., Henderson M.A., Thompson E.W. Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin. Exp. Metastasis. 2004, 21:19-29.
156. Adwan H., Bauerle T., Najajreh Y., Elazer V., Golomb G., Berger M.R. Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int. J. Oncol. 2004, 24:1235-1244.
157. Saxne T., Zunino L., Heinegard D. Increased relase of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis. Arthritis Rheum. 1995, 38:82-90.
158. Ohno U., Matsuyama T., Ishii S., Hata H., Kuboki Y. Measurement of human immunoreactive bone sialoprotein (BSP) in normal adults and in pregnant women. J. Bone Miner. Res. 1995, 10(Suppl 1):S476. (Abstract).
159. Karmatschek M., Maier I., Seibel M.J., Woitge H.W., Ziegler R., Armbruster F.P. Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay. Clin. Chem. 1997, 43:2076-2082.
160. Cogan G., Bansal A.K., Ibrahim S., Zhu B., Goldberg H.A., Ganss B., Cheifetz S., Armbruster F.P., Sodek J. Analysis of human bone sialoprotein in normal and pathological tissues using a monoclonal antibody (BSP 1.2 mab). Connect. Tissue Res. 2004, 45:60-71.
161. Seibel M.J., Woitge H.W., Pecherstorfer M., Karmatschek M., Horn E., Ludwig H., Armbruster F.P., Ziegler R. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J. Clin. Endocrinol. Metab. 1996, 81:3289-3294.
162. Woitge H.W., Pecherstorfer M., Horn E., Keck A.V., Diel I.J., Bayer P., Ludwig H., Ziegler R., Seibel M.J. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br. J. Cancer 2001, 84:344-351.
163. Jung K., Lein M., Stephan C., Von H.K., Semjonow A., Sinha P., Loening S.A., Schnorr D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int. J. Cancer 2004, 111:783-791.
164. Woitge H.W., Knothe A., Witte K., Schmidt-gayk H., Ziegler R., Lemmer B., Seibel M.J. Circannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: A prospective study. J. Bone Miner. Res. 2000, 15:2443-2450.
165. Faust D., Menge F., Armbruster F.P., Lembcke B., Stein J. Increased serum bone sialoprotein concentrations in patients with Crohn's disease. Z. Gastroenterol. 2003, 41:243-247.
166. Taylor A.K., Linkhart S., Mohan S., Christenson R.A., Singer F.R., Baylink D.J. Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. J. Clin. Endocrinol. Metab. 1990, 70:467-472.
167. Ivaska K.K., Hellman J., Likojarvi J., Kakonen S.M., Gerdhem P., Akesson K., Obrant K.J., Pettersson K., Vaananen H.K. Identification of novel proteolytic forms of osteocalcin in human urine. Biochem. Biophys. Res. Commun. 2003, 306:973-980.
168. Ivaska K.K., Hentunen T.A., Vaaraniemi J., Ylipahkala H., Pettersson K., Vaananen H.K. Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J. Biol. Chem. 2004, 279:18361-18369.
169. Cloos P.A., Christgau S. Characterization of aged osteocalcin fragments derived from bone resorption. Clin. Lab. 2004, 50:585-598.
170. Gerdhem P., Ivaska K.K., Alatalo S.L., Halleen J.M., Hellman J., Isaksson A., Pettersson K., Vaananen H.K., Akesson K., Obrant K.J. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J. Bone Miner. Res. 2004, 19:386-393.
171. Ivaska K.K., Kakonen S.M., Gerdhem P., Obrant K.J., Pettersson K., Vaananen H.K. Urinary osteocalcin as a marker of bone metabolism. Clin. Chem. 2005, 51:618-628.
172. Romas N.A., Rose N.R., Tannenbaum M. Acid phosphatase: New developments. Hum. Pathol. 1979, 10:501-512.
173. Yam L.T. Clinical significance of human acid phosphatases. Am. J. Med. 1974, 56:604-616.
174. Li C.Y., Chuda R.A., Lam K.-W., Yam L.T. Acid phosphatases in human plasma. J. Lab. Clin. Med. 1973, 82:446-460.
175. Lam K.W., Lai L., Yam L.T. Tartrate-resistant acid phosphatase activity measured by electrophoresis an acrylamid gel. Clin. Chem. 1978, 24:309-312.
176. Vaes G., Jacques P. The assay of acid hydrolases and other enzymes in bone tissue. Biochem. J. 1965, 97:380-388.
177. Wergedal J.E. Characterization of bone acid phosphatase activity. Proceeding of the Society for Experimental Biology 1970, 134:244-247.
178. Hammarstrom L.E., Hanker J.S., Toverud S.U. Cellular differences in acid phosphatase isoenzymes in bone and teeth. Clin. Orthop. 1971, 78:151-155.
179. Lau K.-H., Stepan J.J., Yoo A., Mohan S., Baylink D.J. Evidence that tartrate-resistant acid phosphatases from osteoclastomas and hairy cell leukemia spleen are members of a multigene family. Int. J. Biochem. 1991, 23:1237-1244.
180. Wergedal J., Lau K.-H.W., Baylink D.J. Fluoride and bovine bone extract influence cell proliferation and phosphatase activities in human bone cell cultures. Clin. Orthop. Rel. Res. 1988, 233:274-282.
181. Bianco P., Ballanti P., Bonucci E. Tartrate resistant acid phosphatase activity in rat osteoblasts and osteocytes 1988, (Un Pub).
182. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calc. Tiss. Int. 1982, 34:285-290.
183. Wergedal J.E., Baylink D.J. Characterization of cell isolated and cultured from human bone. Proceeding of the Society for Experimental Biology 1984, 176:27-31.
184. Lam K.W., Lee P., Li C.Y., Yam L.T. Immunological and biochemical evidence for identity of tartrate-resistenti soenzymes of acid phosphatases from human spleen and tissues. Clin. Chem. 1980, 26:420-422.
185. K.H.W.Lau, Onishi T., Wergedal J.E., Singer F.R., Baylink D.J. Characterization and assay of tartrate-resistent acid phosphatase activity in serum: potential use to assess bone resorption. Clin. Chem. 1987, 33:458-462.
186. Stepan J.J., Pospichal J., Presl J., Pacovsky V. Bone loss and biochemical indices of bone remodelling in surgically induced postmenopausal women. Bone 1987, 8:279-284.
187. Stepan J.J., Tesarova A., Havranek T., Jodl J., Normankova J., Pacovsky V. Age and sex dependency of the biochemical indices of bone remodelling. Clin. Chem. Acta. 1985, 151:273-283.
188. Stepan J.J., Silinkova-Malkova E., Havranek T., Formankova J., Zichova M., Lachmanova J., Strakova M., Broulik P., Pacovsky V. Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin. Chem. Acta. 1983, 133:189-200.
189. Cooper J.D.H., Turnell D.C., Price C.P. The estimation of serum acid phosphatase using alpha-naphthyl phosphate as substrate: observation on the use of fast red TR salt in the assay. Clin. Chem. 1982, 126:297-306.
190. Bais R., Edwards J.B. An optimized continuous-monotoring procedure for semiautomated determination of serum acid phosphatase activity. Clin. Chem. 1976, 22:2025-2028.
191. Lam K.W., Burke D.S., Siemens M., Cipperly V., Li C.Y., Yam L.T. Characterization of serum acid phosphatase associated with dengue hemorrhagic fever. Clin. Chem. 1982, 28:2296-2299.
192. Warren R.J., Moss D.W. An automated continuous-monitoring procedure for the determination of acid phosphatase activity in serum. Chim. Acta. 1977, 77:179-188.
193. Omene J.A., Glew R.H., Baig H.A., Robinson D.B., Brock W., Chamber J.P. Determination of serum acid and alkaline phosphatase using 4-methylumbelliferyl phosphate. Afr. J. Med. Sci. 1981, 10:9-18.
194. Nakanishi M., Yoh K., Uchida K., Maruo S., Matsuoka A. Improved method for measuring tartrate-resistant acid phosphatase activity in serum. Clin. Chem. 1998, 44:221-225.
195. Lam K.W., Siemens M., Sun T., Li C.Y., Yam L.T. Enzyme-immunoassay for tartrate-resistent acid phosphatase. Clin. Chem. 1982, 28:467-470.
196. Echetebu Z.O., Cox T.M., Moss D.W. Antibodies to porcine uteroferrin used in measurement of human tartrate-resistant acid phosphatase. Clin. Chem. 1987, 33(No 10):1832-1836.
197. Whitaker K.B., Cox T.M., Moss D.W. An immunoassay of human band-5 ("tartrate-resistent") acid phosphatase that involves the use of anti-porcine uteroferrin antibodies. Clin. Chem. 1989, 35:86-89.
198. Cheung C.K., Panesar N.S., Haines C., Masarei J., Swaminathan R. Immunoassay of a tartrate-resistant acid phosphatase in serum. Clin. Chem. 1995, 41:679-686.
199. Kraenzlin M.E., Lau K.-H.W., Liang L., Freeman T.K., Singer F.R., Stepan J., Baylink D.J. Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J. Clin. Endocrinol. Metab. 1990, 71:442-451.
200. Ott S.M. Clinical effects of bisphosphonates in involutional osteoporosis. J. Bone Miner. Res. 1993, 8(Suppl. 2):S597-S606.
201. Halleen J., Hentunen T.A., Karp M., Käkönen S.M., Petterson K., Väänänen H.K. Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. J. Bone Miner. Res. 1998, 13:683-687.
202. Pasco J.A., Henry M.J., Kotowicz M.A., Sanders K.M., Seeman E., Pasco J.R., Schneider H.G., Nicholson G.C. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J. Bone Miner. Res. 2004, 19:752-758.
203. Halleen J., Hentunen T.A., Hellman J., Vaananen H.K. Tartrate-resistant acid phosphatase from human bone: purification and development of an immunoassay. J. Bone Miner. Res. 1996, 11:1444-1452.
204. Halleen J., Alatalo S., Suominen H., Cheng S., Janckila A.J., Väänänen H.K. Tartrate-resistent acid phosphatase 5b: a novel serum marker of bone resorption. J. Bone Miner. Res. 2000, 15:1337-1345.
205. Chu P., Chao T.Y., Lin Y.F., Janckila A.J., Yam L.T. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am. J. Kidney Dis. 2003, 41:1052-1059.
206. Seibel M.J. Molecular marker on bone turnover biochemical, technical and analytical aspects. Osteoporos Int 2000, 11(Suppl. 6):18-29.
207. Stepan J.J., Lachmanova J., Strakova M., Pacovsky V. Serum osteocalcin, bone alkaline phosphatase isoenzyme and plasma tartrate resistent acid phosphatase in patients on chronic maintenance hemodialysis. Bone Min. 1987, 3:177-183.
208. Gelb B.D., Shi G.P., Chapman H.A., Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273:1236-1238.
209. Saftig P., Hunziker E., Wehmeyer O., Jones S., Boyde A., Rommerokirch W., Moritz J.D., Schu P., von Figura K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl Acad. Sci. USA 1998, 95:13453-13458.
210. Gowen M., Lazner F., Dodds R., Kapadia R., Feild J., Tavaria M., Bertoncello I., Drake F., Zavarselk S., Tellis I., Hertzog P., Debouck C., Kola I. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 1999, 14:1654-1663.
211. Goto T., Yamaza T., Tanaka T. Cathepsins in the osteoclast. J. Electron. Microsc. (Tokyo) 2003, 52:551-558.
212. Meier C., Meinhardt U., Greenfield J.R., Nguyen T.V., de Winter J., Dunstan C., Seibel M.J. Serum cathepsin K levels reflect osteoclastic activity in postmenoopausal osteoporosis and Paget's disease of bone. Clin. Lab. 2006, (in press).
213. Lang T.H., Willinger U., Holzer G. Soluble cathepsin-L: a marker of bone resorption and bone density. J. Lab. Clin. Med. 2004, 144:163-166.
214. Robins S.P. Measurement of pyridinium crosslinks by HPLC and immunoassay. Calcium Regulating Hormones and Markers of Bone Metabolism: Measurement and Interpretation 1997, 135-140. Clin Lab Publications, Heidelberg, Germany. H. Schmidt-gayk (Ed.).